Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
New conditioning regimens are still needed to maximize efficacy and limit treatment-related
deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past
several years, the investigators have evaluated several new conditioning regimens that
incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has
synergistic activity with alkylating agents. Recent data have suggested that fludarabine may
be used in combination with standard doses of oral or IV busulfan, thus reducing the toxicity
previously observed with cyclophosphamide/ busulfan regimens.